KOSPIHolding Companies000640

Dong-A Socio Holdings

₩88,700▲ 0.23%2026-11-18 close
Market Cap
₩597.2B
Turnover
₩400M
Volume
4.3K
Shares out.
6.7M
PER
8.6×
PBR
0.5×
EPS
₩10,292
Dividend Yield
1.92%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,700 per share · Prices as of the 2026-11-18 close

01

Report overview

Dong-A Socio Holdings: Cash engine back under one roof

After absorbing its wholly owned healthcare subsidiary on October 1, 2026, Dong-A Socio Holdings operates as a business holding company with consumer health cash flow on its own books. Revenue, operating profit and net income attributable to controlling shareholders rose for three straight years through 2025, but net income attributable to controlling shareholders fell year on year in the third quarter of 2026, so earnings stability is the next item to watch.

  1. 1

    Structure: the holding company absorbed its 100%-owned subsidiary on October 1, 2026 without issuing new shares, leaving shareholding unchanged.

  2. 2

    Annual growth: revenue rose from KRW 1.01 trillion in 2022 to KRW 1.43 trillion in 2025, and operating profit from KRW 37.9 billion to KRW 97.8 billion.

  3. 3

    Q3 2026: revenue of KRW 431 billion (up 12.7% YoY), operating profit of KRW 35.1 billion (up 5.4%) and net income attributable to controlling shareholders of KRW 31.4 billion (down 33.2%), so profit trends diverged by line.

  4. 4

    Cash generation: operating cash flow was KRW 227.4 billion in 2025, and the debt ratio was 80.6% at the end of 2025.

  5. 5

    Weak spots: the fourth quarter of 2025 turned to a net loss attributable to controlling shareholders of KRW 11.5 billion, and subsidiary volatility remains, including shipment delays at the CMO unit and lower profit at the logistics unit.

02

Business structure

Dong-A Socio Holdings absorbed its wholly owned healthcare subsidiary on October 1, 2026 and became a business holding company. The combined company has a holding function for group governance and investment and a business function for consumer healthcare.

Before the merger, the subsidiary's core lines were Bacchus, over-the-counter (OTC) medicines, health functional foods (HTC), dermo-cosmetics and household products.

In the third quarter of 2026, the subsidiary's revenue of KRW 227 billion comprised Bacchus at KRW 88.8 billion (up 2.5% YoY), OTC at KRW 72.6 billion (up 27.2%) and HTC at KRW 48.2 billion (up 2.0%). Its nine-month revenue reached KRW 643.2 billion (up 16.6%) and operating profit KRW 79.7 billion (up 15.1%).

The logistics affiliate posted third-quarter revenue of KRW 121.5 billion (up 10.8%), but its operating profit fell to KRW 2.7 billion (down 57.9%).

The CMO subsidiary's revenue dropped 20.9% to KRW 24.9 billion because commercial product shipments were deferred, while its operating profit rose 168.3% to KRW 4.9 billion.

Prescription drugs and new drug development sit with the affiliate Dong-A ST, and the holding company owned 80.4% of the CMO unit at the end of 2025. Several pharmaceutical groups are also absorbing subsidiaries to bring cash flow back to the parent.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩382.6B₩33.3B8.7%
2025Q4₩371.9B₩16B4.3%
2026Q1₩351B₩19.1B5.5%
2026Q2₩412.4B₩39B9.4%
2026Q3₩431B₩35.1B8.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1T₩37.9B₩11.2B3.7%1.1%73.4%
2023₩1.1T₩76.9B₩58B6.8%5.7%90.5%
2024₩1.3T₩82.1B₩58B6.2%5.5%90.8%
2025₩1.4T₩97.8B₩90.9B6.8%8.0%80.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a reported basis, annual revenue grew from KRW 1.01 trillion in 2022 to KRW 1.43 trillion in 2025. Revenue was KRW 1.13 trillion in 2023 (up 11.5%), KRW 1.33 trillion in 2024 (up 17.8%) and KRW 1.43 trillion in 2025 (up 7.2%), rising for three consecutive years from 2023 through 2025.

Operating profit rose from KRW 37.9 billion in 2022 to KRW 76.9 billion in 2023 (up 103.1%), then KRW 82.1 billion in 2024 (up 6.8%) and KRW 97.8 billion in 2025 (up 19.1%). The operating margin climbed from 3.7% in 2022 to 6.8% in 2023, slipped to 6.2% in 2024 and recovered to 6.8% in 2025.

Net income attributable to controlling shareholders jumped to KRW 58 billion in 2023 (up 420.0%) but was flat at KRW 58 billion in 2024 (up 0.1%). It reached KRW 90.9 billion in 2025 (up 56.7%), while net income including non-controlling interests was KRW 91.5 billion, a different figure.

Operating cash flow was KRW 75.9 billion in 2022, KRW 158.7 billion in 2023, KRW 83 billion in 2024 and KRW 227.4 billion in 2025, the largest of the four years.

By quarter, revenue in the fourth quarter of 2025 was KRW 371.9 billion (down 2.8% from the prior quarter) and operating profit was KRW 16 billion (down 52.1%), and the company posted a net loss attributable to controlling shareholders of KRW 11.5 billion.

In the first quarter of 2026, revenue was KRW 351 billion, operating profit KRW 19.1 billion and net income attributable to controlling shareholders KRW 20.6 billion, a return to profit. The second quarter improved further, with revenue of KRW 412.4 billion (up 17.5%) and operating profit of KRW 39 billion (up 103.6%).

Third-quarter revenue reached KRW 431 billion (up 4.5% from the prior quarter), but operating profit of KRW 35.1 billion fell 9.9% from the prior quarter. Net income attributable to controlling shareholders of KRW 31.4 billion was down 33.2% year on year, and the last four quarters total KRW 69.6 billion. The debt ratio rose from 73.4% in 2022 to 90.8% in 2024 before easing to 80.6% in 2025.

05

Industry analysis

Korean pharmaceutical and healthcare groups have been absorbing subsidiaries to bring their operations and cash flow back to the parent. Dong-A Socio Holdings' merger fits this pattern, and the company said it aims to reduce the structural discount applied to pure holding companies and to unify decision-making.

The company also described eliminating the holding-company discount linked to concerns over overlapping listings as one purpose of the merger.

Its core over-the-counter business depends on consumer brand recognition, and the company is building on the Bacchus and OTC brands to widen distribution and enter overseas markets. The company also highlighted that some of its products have gained word-of-mouth popularity among tourists.

OTC segment revenue grew 27.2% in the third quarter of 2026, well ahead of Bacchus at 2.5% and HTC at 2.0% in the same period. The group also lost its long-held position as the top pharmaceutical company by revenue after the 2013 holding-company split, which is part of the context for its current standing.

Pricing-policy changes such as drug price reforms are cited as operating-environment shifts for the industry, and a company with a large OTC share is exposed to pricing and regulatory conditions. Other biotech peers have also decided to absorb subsidiaries in recent months.

06

Outlook

The company has outlined three directions after the merger. First, operating cash generated by its own business can now be used directly for R&D, new businesses and M&A. Second, it plans to expand e-commerce channels, enter global distribution networks and grow overseas consumer healthcare brands.

Third, it set a goal of raising the share of overseas revenue. At its third-quarter 2026 earnings release, the company said it continues to post positive results on steady growth across its main business segments.

The merger is expected to have a limited effect on consolidated results, but the parent's own earnings and cash flow now flow directly into its standalone figures, which is a change.

The first checkpoint is whether shipments resume at the CMO subsidiary, since its commercial product shipments were deferred and its third-quarter revenue fell, making shipment timing a variable for subsidiary recovery.

The logistics subsidiary grew volume, but its third-quarter operating profit declined, so whether its profitability recovers matters. In the 2026 annual report, the next regular filing, standalone operating margin and operating cash flow will show how the merger is working.

07

Valuation

PER
8.6×
PBR
0.5×
ROE
5.9%
EPS
₩10,292
BPS
₩180,825
Dividend per share
₩1,700

Price-to-book stands well below 1x, which places the stock in a discount to net asset value.

Holding companies have long faced the holding-company discount argument, the view that subsidiary value is not fully reflected in the share price, and the merger has been explained as a structural change aimed at reducing that discount.

The last four quarters total KRW 69.6 billion in net income attributable to controlling shareholders, so any earnings multiple should be read against that base. The recovery from KRW 11.2 billion in 2022 to KRW 90.9 billion in 2025 is the starting point for interpreting the multiple.

However, the fourth quarter of 2025 was a net loss and third-quarter 2026 net income attributable to controlling shareholders fell year on year, so quarterly swings complicate that reading.

With cash flow now accumulating directly at the surviving entity, how dividends and investment funds are used may become a new basis for market assessment. How the market values the merger will become clearer through upcoming quarterly results and regular filings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Direct use of its own cash generation

Operating cash flow was KRW 227.4 billion in 2025, close to three times the KRW 75.9 billion recorded in 2022. After the merger that cash flows directly into the surviving entity, which can fund R&D, new businesses and M&A.

The company said it will pair investment decisions and operations under one board and management team to speed execution.

OTC-led top-line growth

OTC segment revenue at the subsidiary rose 27.2% to KRW 72.6 billion in the third quarter of 2026, and the KRW 15.5 billion increase accounted for about 58% of the segment's total revenue gain. Nine-month revenue rose 16.6% to KRW 643.2 billion. Bacchus and HTC also kept growing at 2.5% and 2.0%, respectively.

Earnings recovery and return to profit

Net income attributable to controlling shareholders rose from KRW 11.2 billion in 2022 to KRW 90.9 billion in 2025. It turned to profit at KRW 20.6 billion in the first quarter of 2026, then rose for two straight quarters to KRW 29.1 billion and KRW 31.4 billion. The last four quarters total KRW 69.6 billion.

09

Bear factors

Third-quarter profit decline and margin pressure

Net income attributable to controlling shareholders was KRW 31.4 billion in the third quarter of 2026, down 33.2% year on year, while operating profit of KRW 35.1 billion rose 5.4%. The operating margin fell from 8.7% a year earlier to 8.1%. The items explaining the gap between operating and net profit are the ones to verify in the 2026 annual report.

Uneven subsidiary performance

The CMO subsidiary's third-quarter revenue fell 20.9% to KRW 24.9 billion, and its nine-month revenue fell 25.1% to KRW 56.6 billion. The logistics subsidiary's third-quarter revenue rose 10.8%, but its operating profit fell 57.9% to KRW 2.7 billion. Cumulative operating profit at the two units declined to KRW 5.6 billion and KRW 13.4 billion, respectively.

Quarterly earnings volatility

The fourth quarter of 2025 turned to a net loss attributable to controlling shareholders of KRW 11.5 billion, while operating profit fell 52.1% from the prior quarter to KRW 16 billion. Quarterly swings can be masked by annual totals, which the last four quarters' KRW 69.6 billion illustrates. The debt ratio of 80.6% at the end of 2025 is below the 90.8% of 2024 but above the 73.4% of 2022.

10

Risk factors

Governance and investment concentration

The merger concentrates business operations and investment decisions in one board and management team. Faster decisions are an advantage, but if M&A and new-business spending grow, the link between core cash flow and investment returns may become harder to read. Investment in new drugs and biotech is still at a stage where it has not yet shown up in reported results.

Regulatory and pricing environment

The OTC business is exposed to drug pricing rules and regulation. Pricing-policy changes such as drug price reforms are affecting the industry, and changes in prices or distribution terms could affect OTC growth and margins. Because Bacchus and OTC account for a large share of the subsidiary's revenue, the exposure is broad.

Overseas expansion and subsidiary execution

Entering overseas distribution networks, expanding e-commerce and bringing a cosmetics brand to the United States are growth pillars the company has outlined. Raising the overseas revenue share could bring higher marketing and distribution costs that weigh on profitability.

Shipment timing at the CMO unit and profitability at the logistics unit remain subsidiary-level risks to monitor.

11

What to watch next

  1. After January 2027 (Q4 and full-year 2026 preliminary results; timing to be confirmed by disclosure)

    Checks whether nine-month revenue of KRW 1.19 trillion and operating profit of KRW 93.2 billion momentum continued in the fourth quarter, and whether the company moved out of the loss seen in the fourth quarter of 2025.

  2. By end-March 2027 (2026 annual report filing)

    This is the first full-year regular filing after the merger, showing standalone operating margin, operating cash flow and the gap between net income attributable to controlling shareholders and total net income.

  3. Around late April 2027 (Q1 2027 earnings, typical schedule)

    Checks whether shipments of commercial products resume at the CMO unit and whether operating profit recovers at the logistics unit.

12

Overall view

Dong-A Socio Holdings became a business holding company through its absorption merger of the healthcare subsidiary on October 1, 2026, and the surviving entity now holds the consumer healthcare cash flow from Bacchus, OTC and health functional foods directly.

On a reported basis, revenue and operating profit have grown since 2022, and net income attributable to controlling shareholders rose from KRW 11.2 billion in 2022 to KRW 90.9 billion in 2025.

Third-quarter 2026 revenue of KRW 431 billion rose 12.7% year on year, but net income attributable to controlling shareholders of KRW 31.4 billion fell 33.2%, so the trend diverged by profit line.

Supportive factors are OTC-led top-line growth, unified decision-making with more room to deploy internal cash, and the lower debt ratio in 2025.

Negative factors are uneven subsidiary results, quarterly earnings swings highlighted by the net loss in the fourth quarter of 2025, and the operating margin decline from 8.7% to 8.1% in the third quarter.

Whether the expected elimination of the holding-company discount shows up in the share price, and how quickly, remains to be confirmed. The next checkpoints are the operating margin and operating cash flow in the 2026 annual report, the resumption of CMO shipments, and first-quarter 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. dapharm.com
  2. news.bizwatch.co.kr
  3. m.news.nate.com
  4. medipana.com
  5. thebionews.net
  6. m.news.nate.com
  7. dnews.co.kr
  8. daily.hankooki.com
  9. huffingtonpost.kr
  10. newspost.kr
  11. businesskorea.co.kr
  12. newsclaim.co.kr
  13. businesspost.co.kr
  14. ftoday.co.kr
  15. onews.tv
  16. getnews.co.kr
  17. newswire.co.kr
  18. wolyo.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis